Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability

Cancer Letters

Volumn 284, Issue 2, 2009, Pages 175-181

  Li, Xin ^a   Ling, Wen ^a   Pennisi, Angela ^a   Khan, Sharmin ^a   Yaccoby, Shmuel ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Angiogenesis; Fenretinide; Multiple myeloma; Osteoclastogenesis; Sphingosine 1 phosphate

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CERAMIDE; FENRETINIDE; REACTIVE OXYGEN METABOLITE; SPHINGOSINE 1 PHOSPHATE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CANCER INHIBITION; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MYELOMA CELL; OSTEOCLAST; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FENRETINIDE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYSOPHOSPHOLIPIDS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOIDS; OSTEOBLASTS; OSTEOCLASTS; REACTIVE OXYGEN SPECIES; SPHINGOSINE; TUMOR CELLS, CULTURED;

EID: 69549103081     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.022     Document Type: Article

References (30)

1. Lentzsch S., Ehrlich L.A., and Roodman G.D. Pathophysiology of multiple myeloma bone disease. Hematol. Oncol. Clin. North Am. 21 (2007) 1035-1049
2. Vacca A., and Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 20 (2006) 193-199
3. Richardson P.G., Mitsiades C., Schlossman R., Munshi N., and Anderson K. New drugs for myeloma. Oncologist 12 (2007) 664-689
4. Decensi A., and Costa A. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur. J. Cancer. 36 (2000) 694-709
5. Lieberman R., Crowell J.A., Hawk E.T., Boone C.W., Sigman C.C., and Kelloff G.J. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin. Chem. 44 (1998) 420-427
6. Ulukaya E., and Wood E.J. Fenretinide and its relation to cancer. Cancer Treat. Rev. 25 (1999) 229-235
7. Paulson J.D., Oldham J.W., Preston R.F., and Newman D. Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide. Fundam. Appl. Toxicol. 5 (1985) 144-150
8. Rehman F., Shanmugasundaram P., and Schrey M.P. Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity. Br. J. Cancer. 91 (2004) 1821-1828
9. Andrews W.J., Winnett G., Rehman F., Shanmugasundaram P., Hagen D., and Schrey M.P. Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production. J. Steroid Biochem. Mol. Biol. 94 (2005) 159-165
10. Oridate N., Suzuki S., Higuchi M., Mitchell M.F., Hong W.K., and Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J. Natl. Cancer Inst. 89 (1997) 1191-1198
11. Wu J.M., DiPietrantonio A.M., and Hsieh T.C. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 6 (2001) 377-388
12. Ogretmen B., and Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer. 4 (2004) 604-616
13. Hail Jr. N., Kim H.J., and Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 11 (2006) 1677-1694
14. Yaccoby S., Wezeman M.J., Henderson A., Cottler-Fox M., Yi Q., Barlogie B., and Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 64 (2004) 2016-2023
15. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin. Cancer Res. 11 (2005) 7599-7606
16. Li X., Pennisi A., Zhan F., Sawyer J., Shaughnessy J., and Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br. J. Haematol. 138 (2007) 802-811
17. Yaccoby S., Wezeman M.J., Zangari M., Walker R., Cottler-Fox M., Gaddy D., Ling W., Saha R., Barlogie B., Tricot G., and Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91 (2006) 192-199
18. Yatomi Y. Plasma sphingosine 1-phosphate metabolism and analysis. Biochim. Biophys. Acta 1780 (2008) 606-611
19. van Engeland M., Nieland L., Ramaekers F., Schutte B., and Reutelingsperger C.P. Annexin V-Affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31 (1998) 1-9
20. Bataille R., Chappard D., Marcelli C., Dessauw P., Baldet P., Sany J., and Alexandre C. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest. 88 (1991) 62-66
21. Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F., and Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Brit. J. Haematol. 87 (1994) 503-508
22. Noonan D.M., Benelli R., and Albini A. Angiogenesis and cancer prevention: a vision. Recent Results Cancer Res. 174 (2007) 219-224
23. Shishodia S., Gutierrez A.M., Lotan R., and Aggarwal B.B. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res. 65 (2005) 9555-9565
24. Maceyka M., Milstien S., and Spiegel S. Shooting the messenger: oxidative stress regulates sphingosine-1-phosphate. Circ. Res. 100 (2007) 7-9
25. Melendez A.J. Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets. Biochim. Biophys. Acta 1784 (2008) 66-75
26. Ryu J., Kim H.J., Chang E.J., Huang H., Banno Y., and Kim H.H. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO. J. 25 (2006) 5840-5851
27. Dobrowsky R.T., Kamibayashi C., Mumby M.C., and Hannun Y.A. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 268 (1993) 15523-15530
28. Yang Z., Costanzo M., Golde D.W., and Kolesnick R.N. Tumor necrosis factor activation of the sphingomyelin pathway signals nuclear factor kappa B translocation in intact HL-60 cells. J. Biol. Chem. 267 (1993) 20520-20523
29. Sun S.Y., Li W., Yue P., Lippman S.M., Hong W.K., and Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res. 59 (1999) 2493-2498
30. Kim H.J., Chakravarti N., Oridate N., Choe C., Claret F.X., and Lotan R. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 25 (2006) 2785-2794